-
Mashup Score: 0
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, provides insight into managing moderate to severe anemia in patients with myelofibrosis (MF). It is crucial that clinicians investigate the cause of the anemia and measure erythropoietin levels prior to initiating treatment. The anemia can then be managed with erythropoiesis-stimulating agents (ESAs) or several other agents, such as danazol. Prof. McMullin also emphasizes that ruxolitinib, the frontline treatment option for MF, may decrease hemoglobin levels and worsen anemia; therefore, the novel agent momelotinib will likely become the first choice when treating patients. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Post-ASCO & EHA 2024 Highlights - 6 hour(s) ago
Webinar series by VJHemOnc featuring presentations & discussions on key abstracts in hematological malignancies presented at the ASCO & EHA 2024 meetings.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0The real-world safety and efficacy of CPX-351 in patients with AML - 13 hour(s) ago
Priyanka Mehta, MBBS, MD, FRCP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, briefly discusses the real-world safety and efficacy data collected when using CPX-351 to treat patients with acute myeloid leukemia (AML). These data confirmed the efficacy of the drug in younger patients and answered questions about measurable residual disease (MRD) responses and transplant outcomes. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2BSH 2024 | VJHemOnc - 1 day(s) ago
The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology professionals to discuss advances in the field. The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology professionals to discuss advances in the field. We use cookies to provide the best experience on our website. We also use third party
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5VJHemOnc – The video journal of hematological oncology - 1 day(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Complement inhibition with iptacopan has high efficacy in PNH: insights from APPLY and APPOINT - 2 day(s) ago
Antonio Risitano, MD, PhD, AORN San Giuseppe Moscati Di Avellino, Avellino, Italy, presents encouraging data on the anti-complement agent iptacopan for treating paroxysmal nocturnal hemoglobinuria (PNH), as evidenced by the APPLY-PNH (NCT04558918) and APPOINT-PNH (NCT04820530) trials. In the APPOINT trial, sustained responses, with hemoglobin levels nearing normal in some patients, were observed after 48 weeks. Dr Risitano also addresses the issue of breakthrough hemolysis (BTH) associated with complement inhibitors which has been rare and low severity in these trials. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis - 2 day(s) ago
Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, presents the updated analyses of the PATHFINDER study (NCT03580655) investigating avapritinib, a highly selective KIT D816V inhibitor, in patients with advanced systemic mastocytosis (AdvSM). The responses to treatment have been encouraging, particularly in treatment-naive patients, with significant decreases in mast cell disease burden and improvement in blood counts. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses a survey comparing the use of CAR-T products axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) across 67 European centers for aggressive B-cell lymphoma. Axi-cel emerged as the favored product due to lower lymphocyte apheresis workload, manufacturing availability, and effectiveness. However, tisa-cel was preferred for older patients due to lower toxicity. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
Piers Patten, MBChB, MRCP, FRCPath, PhD, King’s College London, London, UK, discusses the complex issue of selecting a therapy approach for patients with chronic lymphocytic leukemia (CLL). As the number of available treatment options has increased in recent years, physicians now have several agents to choose from. Dr Patten highlights that, when selecting a treatment, there is a need to consider the nature of the patient’s disease, their medical history and comorbidities, and, importantly, their preferences. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA approves fidanacogene elaparvovec, a one-time gene therapy, for adult patients with hemophilia B - 4 day(s) ago
Read about the FDA approval of fidanacogene elaparvovec, a one-time gene therapy, for adults with hemophilia B.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
At #BSH2024, we caught up with Mary Frances McMullin of @queensubelfast, who spoke on the management of moderate to severe anemia in patients with #Myelofibrosis. Click here to watch the interview: 👉 https://t.co/VwbDhXJiCZ #MPNsm #HemOnc @BritSocHaem